In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

Use of [11C]-Methionine PET and Diffusion- / Perfusion-Weighted MR Imaging in Gliomas

Coope DJ

[Thesis].The University of Manchester;2010.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Use our list of Related resources to find this item elsewhere. Alternatively, request a copy from the Library's Document supply service.

Abstract

Introduction - Low-grade gliomas are a sub-group of primary brain tumours that typically affect young adults and which present specific challenges to conventional diagnostic imaging. They demonstrate a pattern of growth whereby tumour cells infiltrate healthy brain tissue without distortion of the surrounding brain or blood-brain barrier integrity. These features limit the capacity of conventional neuro-imaging strategies to effectively delineate the tumour extent or characterise the degree of 'malignancy'. One solution is to apply multiple imaging modalities to image different aspects of the tumour behaviour, analogous to histological classification based upon changes in mitotic activity, cellular atypia, microvascular proliferation and necrosis. Published information regarding how imaging techniques that address these parameters correlate within the tumour volume is limited. This reflects the technical challenges in acquiring and processing data at an adequate spatial resolution to characterise small but heterogenous tumours. In this thesis, following a series of experiments seeking to optimise the sensitivity and reproducibility of PET analysis in gliomas, a prospective multi-modal neuro-imaging study is presented addressing this need. Methods - Retrospective [11C]-methionine PET (MET PET) data made available through a collaboration with the Max-Planck Institute for Neurological Research in Cologne was carried out first to address the optimal method of analysis of PET data in gliomas. A normal methionine uptake map was created and its use in the analysis of patient scans validated against a conventional approach. Automated methods for delineating the extent of abnormal methionine uptake and identifying the region of peak uptake were developed and evaluated to optimise the reproducibility of the approach. High-resolution MET PET and a comprehensive MRI brain tumour protocol were then acquired prospectively in 20 subjects in Manchester. Detailed analysis of the peak uptake and extent of abnormal tissue defined using PET and MRI modalities including structural, diffusion- and perfusion-weighted techniques was performed. Results - Evaluation of methionine uptake with respect to population normal data, the 'RatioMap' technique, yielded peak uptake measurements that correlated closely with a conventional approach (r = 0.97) but with improved reproducibility. The constrained 3D region-growing algorithm designed to delineate the abnormal region was shown to be reproducible and to generate volumes that correlated with tumour grade. High-resolution multi-modal data in suspected low-grade gliomas demonstrated consistent correlation between peak methionine uptake ratio and peak regional cerebral blood volume (r = 0.85) but with disparity between the location of the maximal uptake regions (mean distance = 11.2mm). Significant correlation was seen between multi-modal MRI and PET ‘tumour’ volumes (r = 0.91) but with substantially larger MRI defined abnormal volumes (ratio = 2.0) including small regions identified as abnormal by multiple MRI parameters but normal on PET imaging. Conclusion - A novel method to enhance the reproducibility of analysis of MET PET images in gliomas has been presented and validated but there remains no single imaging modality capable of fully characterising glioma extent and 'malignancy' non-invasively. Considerable correlation between PET and MRI tumour biomarkers has been demonstrated but there are significant differences between the regions identified as the 'most malignant' for biopsy targeting and the extent of potentially tumour bearing tissue. Combined use of diffusion- and perfusion-weighted MRI parameters can provide results very closely correlated to the PET findings but cannot yet completely replace the use of nuclear medicine techniques. The use of multi-modal approaches to tumour characterisation as demonstrated in this study provides the most effective currently available approach to fully characterise a suspected glioma.

Bibliographic metadata

Type of resource:
Content type:
Type of thesis:
Author(s) list:
Degree type:
PhD in Medicine
Publication date:
Total pages:
226
Table of contents:
1 Contents 11.1 Table of Contents 11.2 List of Tables 71.3 List of Figures 91.4 Abstract 131.5 Declaration 151.6 Copyright Statement 151.7 Acknowledgments 161.8 Dedication 181.9 Abbreviations 192 Background / Context 222.1 Study Outline and Aims / Hypotheses 242.2 Thesis Structure 262.3 Study Governance 262.4 Role of the Author in the Project 283 Introduction / Review of Previous Work 313.1.1 Incidence of Low-Grade Gliomas 313.1.2 Growth and Progression 323.1.3 Genetic Abnormalities in Gliomas 333.1.4 Alterations in Growth Factor Receptor Expression 373.1.5 Management 393.2 Positron Emission Tomography 413.2.1 [18F]-fluoro-2-deoxyglucose PET in Gliomas 423.2.2 Amino Acid PET and Altered Amino Acid Transport in Gliomas 433.2.3 The High Resolution Research Tomograph 483.3 Magnetic Resonance Imaging 493.3.1 Perfusion-Weighted MRI 503.3.2 Diffusion-Weighted MRI and Diffusion Tensor Imaging 523.4 Image Processing 543.4.1 Inter-Individual Co-Registration / Spatial Normalisation 553.4.2 Intensity Scaling of PET Data for Group Analysis 563.4.3 Analysis of Amino Acid PET Studies in Brain Tumours 574 Methods: 594.1 Evaluation of Normal Methionine Uptake 594.1.1 MPIfNF Patient Group 1 – Earliest Available Scans 594.1.2 Development of Normal Methionine Uptake Map 604.1.3 Evaluation of Co-Registration Method in Template Preparation 644.1.4 Analysis of Tracer Uptake by Anatomical Regions and Evaluation of Intensity Normalisation Methods 654.2 Application of Normal Methionine Uptake Map to Gliomas 674.2.1 Development of Python tool for standardised image analysis and method evaluation 684.2.2 Evaluation of Conventional Single Reference Region Techniques for the Interpretation of MET PET Scans in Gliomas 724.2.3 Correlation of Ratio to Normal Uptake Map with Ratio to Contralateral Reference Value 724.2.4 Evaluation of Affine and Non-Linear Co-Registration Techniques 734.2.5 Median Ratio Intensity Normalisation 754.2.6 Evaluation of Tumour Extent Using the ‘RatioMap’ Compared to a Single Reference Region Technique 764.3 Determining and Characterising the Volume of Abnormal Methionine Uptake in Gliomas 774.3.1 Constrained 3D Region-Growing Method 784.3.2 Evaluation of Tumour Biomarkers based upon Constrained Region-Growing Technique 824.3.3 Application of Constrained Region-Growing Technique to Follow-up Data 874.4 High-Resolution Methionine PET and Diffusion- / Perfusion-Weighted MRI in Low-Grade Gliomas – Study Design and Normal Variability of Measurements 904.4.1 Study Design 904.4.2 WMIC Patient Group 904.4.3 Image Acquisition 934.4.4 Image Processing for MRI Data 954.4.5 Spatial Normalisation 984.4.6 Assessment of Intra-individual Variability 984.4.7 Intensity Scaling for MRI Metrics 994.5 High-Resolution Methionine PET and Diffusion- / Perfusion-Weighted MRI in Low-Grade Gliomas – Correlation of PET and MRI Tumour Biomarkers 1004.5.1 Peak Methionine Uptake 1004.5.2 Correlation of Peak Methionine Uptake with Diffusion and Perfusion Measurements 1004.5.3 Evaluation of Tumour Extent 1015 Results: 1045.1 Evaluation of Normal Methionine Uptake 1045.1.1 Development of Normal Methionine Uptake Map 1045.1.2 Evaluation of Co-Registration Method in Template Preparation 1055.1.3 Analysis of Tracer Uptake by Anatomical Regions and Evaluation of Intensity Normalisation Methods 1065.2 Application of Normal Methionine Uptake Map to Gliomas 1085.2.1 Evaluation of Conventional Single Reference Region Techniques for the Interpretation of MET PET Scans in Gliomas 1085.2.2 Correlation of Ratio to Normal Uptake Map with Ratio to Contralateral Reference Value 1095.2.3 Correlation of Tumour Grade with Maximal Change in Ratio to Normal Map 1105.2.4 Evaluation of Co-Registration and Intensity Normalisation Methods in Disease 1125.2.5 Evaluation of Tumour Extent Using ‘RatioMap’ Compared to a Single Reference Region Technique 1135.3 Determining and Characterising the Volume of Abnormal Methionine Uptake in Gliomas 1155.3.1 Method Evaluation 1155.3.2 Evaluation of Tumour Biomarkers based upon Constrained Region-Growing Technique 1185.3.3 Application to Follow-up Data 1205.4 High-Resolution Methionine PET and Diffusion- / Perfusion-Weighted MRI in Low-Grade Gliomas – Study Design and Normal Variability of Measurements 1235.4.1 Spatial Normalisation 1255.4.2 Intensity Scaling for MRI Metrics 1295.4.3 Assessment of Intra-individual Variability 1305.5 High-Resolution Methionine PET and Diffusion- / Perfusion-Weighted MRI in Low-Grade Gliomas – Correlation of PET and MRI Tumour Biomarkers 1325.5.1 Peak Methionine Uptake 1325.5.2 Correlation of Peak Methionine Uptake with Diffusion and Perfusion Measurements 1335.5.3 Evaluation of Tumour Extent 1356 Discussion 1446.1 Analysis of MET PET Data in Gliomas by Reference to Population Normal Data 1446.2 Determining and Characterising the Volume of Abnormal Methionine Uptake in Gliomas 1496.3 High-Resolution Methionine PET and Diffusion- / Perfusion-Weighted MRI in Low-Grade Gliomas 1546.4 Correlation of HRRT PET and MRI Tumour Biomarkers 1567 Conclusion 1628 Appendices: 1658.1 Appendix A: Published Abstracts / Papers 1658.1.1 Development of a normal 11C-methionine PET uptake map: a novel approach to the evaluation of brain tumors using PET [Abstract] 1668.1.2 Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map 1678.1.3 Evaluation of multiple tumor parameters to improve the non-invasive classification of primary brain tumors with 11C-methionine PET [Abstract] 1778.2 Appendix B: High Resolution Multi-Modal Imaging in Suspected Low-Grade Gliomas – Spatially Normalised Images 1788.3 Appendix C: RatioMap PET Brain Tumour Evaluation Application 1819 References 203
Abstract:
Introduction - Low-grade gliomas are a sub-group of primary brain tumours that typically affect young adults and which present specific challenges to conventional diagnostic imaging. They demonstrate a pattern of growth whereby tumour cells infiltrate healthy brain tissue without distortion of the surrounding brain or blood-brain barrier integrity. These features limit the capacity of conventional neuro-imaging strategies to effectively delineate the tumour extent or characterise the degree of 'malignancy'. One solution is to apply multiple imaging modalities to image different aspects of the tumour behaviour, analogous to histological classification based upon changes in mitotic activity, cellular atypia, microvascular proliferation and necrosis. Published information regarding how imaging techniques that address these parameters correlate within the tumour volume is limited. This reflects the technical challenges in acquiring and processing data at an adequate spatial resolution to characterise small but heterogenous tumours. In this thesis, following a series of experiments seeking to optimise the sensitivity and reproducibility of PET analysis in gliomas, a prospective multi-modal neuro-imaging study is presented addressing this need. Methods - Retrospective [11C]-methionine PET (MET PET) data made available through a collaboration with the Max-Planck Institute for Neurological Research in Cologne was carried out first to address the optimal method of analysis of PET data in gliomas. A normal methionine uptake map was created and its use in the analysis of patient scans validated against a conventional approach. Automated methods for delineating the extent of abnormal methionine uptake and identifying the region of peak uptake were developed and evaluated to optimise the reproducibility of the approach. High-resolution MET PET and a comprehensive MRI brain tumour protocol were then acquired prospectively in 20 subjects in Manchester. Detailed analysis of the peak uptake and extent of abnormal tissue defined using PET and MRI modalities including structural, diffusion- and perfusion-weighted techniques was performed. Results - Evaluation of methionine uptake with respect to population normal data, the 'RatioMap' technique, yielded peak uptake measurements that correlated closely with a conventional approach (r = 0.97) but with improved reproducibility. The constrained 3D region-growing algorithm designed to delineate the abnormal region was shown to be reproducible and to generate volumes that correlated with tumour grade. High-resolution multi-modal data in suspected low-grade gliomas demonstrated consistent correlation between peak methionine uptake ratio and peak regional cerebral blood volume (r = 0.85) but with disparity between the location of the maximal uptake regions (mean distance = 11.2mm). Significant correlation was seen between multi-modal MRI and PET ‘tumour’ volumes (r = 0.91) but with substantially larger MRI defined abnormal volumes (ratio = 2.0) including small regions identified as abnormal by multiple MRI parameters but normal on PET imaging. Conclusion - A novel method to enhance the reproducibility of analysis of MET PET images in gliomas has been presented and validated but there remains no single imaging modality capable of fully characterising glioma extent and 'malignancy' non-invasively. Considerable correlation between PET and MRI tumour biomarkers has been demonstrated but there are significant differences between the regions identified as the 'most malignant' for biopsy targeting and the extent of potentially tumour bearing tissue. Combined use of diffusion- and perfusion-weighted MRI parameters can provide results very closely correlated to the PET findings but cannot yet completely replace the use of nuclear medicine techniques. The use of multi-modal approaches to tumour characterisation as demonstrated in this study provides the most effective currently available approach to fully characterise a suspected glioma.
Keyword(s):

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:207525
Created by:
Coope, David
Created:
13th September, 2013, 17:04:30
Last modified by:
Coope, David
Last modified:
27th April, 2016, 11:59:34

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.